1. Home
  2. CGEM vs LQDT Comparison

CGEM vs LQDT Comparison

Compare CGEM & LQDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$17.60

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Liquidity Services Inc.

LQDT

Liquidity Services Inc.

HOLD

Current Price

$39.63

Market Cap

1.0B

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGEM
LQDT
Founded
2016
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Catalog/Specialty Distribution
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.0B
IPO Year
2020
2005

Fundamental Metrics

Financial Performance
Metric
CGEM
LQDT
Price
$17.60
$39.63
Analyst Decision
Strong Buy
Buy
Analyst Count
8
1
Target Price
$30.13
$40.00
AVG Volume (30 Days)
1.1M
206.2K
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
38.10
EPS
N/A
0.46
Revenue
N/A
$476,669,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$5.20
N/A
P/E Ratio
N/A
$89.28
Revenue Growth
N/A
31.20
52 Week Low
$5.68
$21.67
52 Week High
$19.43
$41.25

Technical Indicators

Market Signals
Indicator
CGEM
LQDT
Relative Strength Index (RSI) 55.99 57.86
Support Level $17.19 $36.36
Resistance Level $19.10 $39.93
Average True Range (ATR) 0.99 1.17
MACD -0.18 0.05
Stochastic Oscillator 60.63 63.92

Price Performance

Historical Comparison
CGEM
LQDT

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

About LQDT Liquidity Services Inc.

Liquidity Services Inc is an online auction marketplace. It manages and sells inventory and equipment for business and government clients by operating a network of e-commerce marketplaces that enable buyers and sellers to transact in an efficient, automated environment offering across different product categories. The company has four reportable segments: GovDeals, Retail Supply Chain Group (RSCG), and Machinio & Software Solutions. It generates majority of its revenue from Retail Supply Chain Group (RSCG) segment which consists of marketplaces that enable corporations located in the United States and Canada to sell excess, returned, and overstocked consumer goods. Geographically, a substantial portion the company's revenue is generated from its business in United States.

Share on Social Networks: